Boston Scientific Corp
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, dire… Read more
Boston Scientific Corp (BSX) - Net Assets
Latest net assets as of September 2025: $23.63 Billion USD
Based on the latest financial reports, Boston Scientific Corp (BSX) has net assets worth $23.63 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($42.71 Billion) and total liabilities ($19.08 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $23.63 Billion |
| % of Total Assets | 55.33% |
| Annual Growth Rate | 18.12% |
| 5-Year Change | 43.56% |
| 10-Year Change | 248.15% |
| Growth Volatility | 58.2 |
Boston Scientific Corp - Net Assets Trend (1991–2024)
This chart illustrates how Boston Scientific Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Boston Scientific Corp (1991–2024)
The table below shows the annual net assets of Boston Scientific Corp from 1991 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $22.00 Billion | +12.66% |
| 2023-12-31 | $19.53 Billion | +11.13% |
| 2022-12-31 | $17.57 Billion | +5.72% |
| 2021-12-31 | $16.62 Billion | +8.46% |
| 2020-12-31 | $15.33 Billion | +10.45% |
| 2019-12-31 | $13.88 Billion | +59.05% |
| 2018-12-31 | $8.72 Billion | +24.45% |
| 2017-12-31 | $7.01 Billion | +4.13% |
| 2016-12-31 | $6.73 Billion | +6.53% |
| 2015-12-31 | $6.32 Billion | -7.64% |
| 2014-12-31 | $6.84 Billion | +4.65% |
| 2013-12-31 | $6.54 Billion | -4.82% |
| 2012-12-31 | $6.87 Billion | -39.49% |
| 2011-12-31 | $11.35 Billion | +0.50% |
| 2010-12-31 | $11.30 Billion | -8.17% |
| 2009-12-31 | $12.30 Billion | -6.37% |
| 2008-12-31 | $13.14 Billion | -12.98% |
| 2007-12-31 | $15.10 Billion | -1.31% |
| 2006-12-31 | $15.30 Billion | +257.26% |
| 2005-12-31 | $4.28 Billion | +6.39% |
| 2004-12-31 | $4.03 Billion | +40.64% |
| 2003-12-31 | $2.86 Billion | +16.01% |
| 2002-12-31 | $2.47 Billion | +22.43% |
| 2001-12-31 | $2.02 Billion | +4.13% |
| 2000-12-31 | $1.94 Billion | +12.24% |
| 1999-12-31 | $1.72 Billion | +109.96% |
| 1998-12-31 | $821.10 Million | -16.74% |
| 1997-12-31 | $986.20 Million | +7.63% |
| 1996-12-31 | $916.30 Million | +21.69% |
| 1995-12-31 | $753.00 Million | +121.47% |
| 1994-12-31 | $340.00 Million | +37.82% |
| 1993-12-31 | $246.70 Million | -0.96% |
| 1992-12-31 | $249.10 Million | +175.86% |
| 1991-12-31 | $90.30 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Boston Scientific Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3802.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $2.67 Billion | 12.28% |
| Common Stock | $17.00 Million | 0.08% |
| Other Comprehensive Income | $275.00 Million | 1.26% |
| Other Components | $18.80 Billion | 86.38% |
| Total Equity | $21.77 Billion | 100.00% |
Boston Scientific Corp Competitors by Market Cap
The table below lists competitors of Boston Scientific Corp ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Lockheed Martin Corporation
NYSE:LMT
|
$106.03 Billion |
|
Comcast Corp
NASDAQ:CMCSA
|
$107.11 Billion |
|
L'Air Liquide S.A
PINK:AIQUF
|
$107.70 Billion |
|
Crowdstrike Holdings Inc
NASDAQ:CRWD
|
$107.94 Billion |
|
Newmont Corporation
AU:NEM
|
$105.12 Billion |
|
Agnico Eagle Mines Limited
NYSE:AEM
|
$105.00 Billion |
|
Sanofi
PINK:SNYNF
|
$104.98 Billion |
|
Kweichow Moutai Co Ltd
SHG:600519
|
$104.84 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Boston Scientific Corp's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 19,282,000,000 to 21,770,000,000, a change of 2,488,000,000 (12.9%).
- Net income of 1,854,000,000 contributed positively to equity growth.
- Share repurchases of 230,000,000 reduced equity.
- Other comprehensive income increased equity by 226,000,000.
- Other factors increased equity by 638,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.85 Billion | +8.52% |
| Share Repurchases | $230.00 Million | -1.06% |
| Other Comprehensive Income | $226.00 Million | +1.04% |
| Other Changes | $638.00 Million | +2.93% |
| Total Change | $- | 12.90% |
Book Value vs Market Value Analysis
This analysis compares Boston Scientific Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.86x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 299.62x to 4.86x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1991-12-31 | $0.24 | $71.20 | x |
| 1992-12-31 | $0.64 | $71.20 | x |
| 1993-12-31 | $0.62 | $71.20 | x |
| 1994-12-31 | $0.81 | $71.20 | x |
| 1995-12-31 | $1.02 | $71.20 | x |
| 1996-12-31 | $1.15 | $71.20 | x |
| 1997-12-31 | $1.23 | $71.20 | x |
| 1998-12-31 | $1.06 | $71.20 | x |
| 1999-12-31 | $2.09 | $71.20 | x |
| 2000-12-31 | $2.36 | $71.20 | x |
| 2001-12-31 | $2.43 | $71.20 | x |
| 2002-12-31 | $2.98 | $71.20 | x |
| 2003-12-31 | $3.40 | $71.20 | x |
| 2004-12-31 | $4.70 | $71.20 | x |
| 2005-12-31 | $5.11 | $71.20 | x |
| 2006-12-31 | $12.01 | $71.20 | x |
| 2007-12-31 | $10.15 | $71.20 | x |
| 2008-12-31 | $8.77 | $71.20 | x |
| 2009-12-31 | $8.16 | $71.20 | x |
| 2010-12-31 | $7.44 | $71.20 | x |
| 2011-12-31 | $7.47 | $71.20 | x |
| 2012-12-31 | $4.88 | $71.20 | x |
| 2013-12-31 | $4.88 | $71.20 | x |
| 2014-12-31 | $5.08 | $71.20 | x |
| 2015-12-31 | $4.71 | $71.20 | x |
| 2016-12-31 | $4.89 | $71.20 | x |
| 2017-12-31 | $5.03 | $71.20 | x |
| 2018-12-31 | $6.23 | $71.20 | x |
| 2019-12-31 | $9.84 | $71.20 | x |
| 2020-12-31 | $10.82 | $71.20 | x |
| 2021-12-31 | $11.59 | $71.20 | x |
| 2022-12-31 | $12.21 | $71.20 | x |
| 2023-12-31 | $13.18 | $71.20 | x |
| 2024-12-31 | $14.65 | $71.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Boston Scientific Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.52%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.07%
- • Asset Turnover: 0.43x
- • Equity Multiplier: 1.81x
- Recent ROE (8.52%) is above the historical average (5.77%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1991 | 46.29% | 18.17% | 1.67x | 1.52x | $32.77 Million |
| 1992 | 22.72% | 17.96% | 1.05x | 1.20x | $31.69 Million |
| 1993 | 28.25% | 18.34% | 1.18x | 1.31x | $45.03 Million |
| 1994 | 23.44% | 17.75% | 1.04x | 1.27x | $45.70 Million |
| 1995 | 1.06% | 0.72% | 1.03x | 1.43x | $-67.30 Million |
| 1996 | 18.24% | 11.43% | 0.97x | 1.65x | $75.47 Million |
| 1997 | 14.12% | 7.44% | 0.95x | 2.00x | $40.68 Million |
| 1998 | -32.20% | -11.84% | 0.57x | 4.74x | $-346.51 Million |
| 1999 | 21.52% | 13.05% | 0.80x | 2.07x | $198.60 Million |
| 2000 | 19.28% | 14.00% | 0.78x | 1.77x | $179.50 Million |
| 2001 | -2.68% | -2.02% | 0.67x | 1.97x | $-255.50 Million |
| 2002 | 15.12% | 12.78% | 0.66x | 1.80x | $126.30 Million |
| 2003 | 16.49% | 13.58% | 0.61x | 1.99x | $185.80 Million |
| 2004 | 26.39% | 18.88% | 0.69x | 2.03x | $659.50 Million |
| 2005 | 14.67% | 10.00% | 0.77x | 1.91x | $199.80 Million |
| 2006 | -23.38% | -45.74% | 0.25x | 2.03x | $-5.11 Billion |
| 2007 | -3.28% | -5.92% | 0.27x | 2.07x | $-2.00 Billion |
| 2008 | -15.50% | -25.29% | 0.30x | 2.06x | $-3.35 Billion |
| 2009 | -8.33% | -12.52% | 0.33x | 2.05x | $-2.26 Billion |
| 2010 | -9.43% | -13.64% | 0.35x | 1.96x | $-2.19 Billion |
| 2011 | 3.88% | 5.79% | 0.36x | 1.88x | $-694.30 Million |
| 2012 | -59.21% | -56.12% | 0.42x | 2.50x | $-4.75 Billion |
| 2013 | -1.85% | -1.69% | 0.43x | 2.56x | $-774.90 Million |
| 2014 | -1.74% | -1.61% | 0.44x | 2.46x | $-803.30 Million |
| 2015 | -3.78% | -3.20% | 0.41x | 2.87x | $-871.00 Million |
| 2016 | 5.15% | 4.14% | 0.46x | 2.69x | $-326.30 Million |
| 2017 | 1.48% | 1.15% | 0.48x | 2.72x | $-597.10 Million |
| 2018 | 19.15% | 17.01% | 0.47x | 2.41x | $798.50 Million |
| 2019 | 33.87% | 43.78% | 0.35x | 2.20x | $3.31 Billion |
| 2020 | -0.54% | -0.83% | 0.32x | 2.01x | $-1.61 Billion |
| 2021 | 6.26% | 8.75% | 0.37x | 1.94x | $-622.30 Million |
| 2022 | 3.97% | 5.50% | 0.39x | 1.85x | $-1.06 Billion |
| 2023 | 8.26% | 11.19% | 0.41x | 1.82x | $-335.20 Million |
| 2024 | 8.52% | 11.07% | 0.43x | 1.81x | $-323.00 Million |
Industry Comparison
This section compares Boston Scientific Corp's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Boston Scientific Corp (BSX) | $23.63 Billion | 46.29% | 0.81x | $105.26 Billion |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |